A single center retrospective study assessing the improved outcomes for patients developing any immune-related adverse events in advanced Non-small Cell Lung Cancer treated with Pembrolizumab monotherapy
Latest Information Update: 08 Oct 2021
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Adenocarcinoma; Non-small cell lung cancer; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- 08 Oct 2021 New trial record
- 14 Sep 2021 Results presented at the 2021 World Conference on Lung Cancer